Univariate analysis of the clinical and molecular parameters and the mutational status of the RHOA gene in the cohort of 121 patients with PTCLs
| RHOA . | Total cases . | WT . | MUT . | P . |
|---|---|---|---|---|
| DX | 121/121 | .016 | ||
| AITL | 48/73 (65.8%) | 25/73 (34.2%) | ||
| PTCL-NOS | 41/48 (85.4%) | 7/48 (14.6%) | ||
| p-ERK | 121/121 | .002 | ||
| Negative | 70/86 (81.4%) | 16/86 (18.6%) | ||
| Positive | 19/35 (54.3%) | 16/35 (45.7%) | ||
| p50 | 118/121 | .166 | ||
| Negative | 25/30 (83.8%) | 5/30 (16.7%) | ||
| Positive | 62/88 (70.5%) | 26/88 (29.5%) | ||
| p52 | 117/121 | .042 | ||
| Negative | 34/40 (85%) | 6/40 (15%) | ||
| Positive | 52/77 (67.5%) | 25/77 (32.5%) | ||
| NF-κB | 119/121 | .068 | ||
| None | 16/18 (88.9%) | 2/18 (11.1%) | ||
| p50 or p52 | 30/37 (81.1%) | 7/37 (18.9%) | ||
| Both | 42/64 (65.6%) | 22/64 (34.4%) | ||
| PD-1 | 88/121 | .024 | ||
| Negative | 24/27 (88.9%) | 3/27 (11.1%) | ||
| Positive | 40/61 (65.6%) | 21/61 (34.4%) | ||
| Sex | 117/121 | .064 | ||
| Male | 47/69 (68.1%) | 22/69 (31.9%) | ||
| Female | 40/48 (83.3%) | 4/48 (16.7%) | ||
| Age at diagnosis | 114/121 | .453 | ||
| <60 y | 33/42 (78.6%) | 9/42 (21.4%) | ||
| ≥60 y | 52/72 (72.2%) | 20/72 (27.8%) | ||
| IPI | 106/121 | .560 | ||
| Low risk | 26/32 (81.2%) | 6/32 (18.8%) | ||
| Low-intermediate risk | 18/27 (66.7%) | 9/27 (33.3%) | ||
| High-intermediate risk | 19/26 (73.1%) | 7/26 (26.9%) | ||
| High risk | 14/21 (66.7%) | 7/21 (33.3%) | ||
| PIT | 94/121 | .962 | ||
| Low risk | 10/14 (71.4%) | 4/14 (28.6%) | ||
| Low-intermediate risk | 26/35 (74.3%) | 9/35 (25.7%) | ||
| High-intermediate risk | 15/22 (68.2%) | 7/22 (31.8%) | ||
| High risk | 16/23 (69.6%) | 7/23 (30.4%) | ||
| ECOG | 102/121 | .479 | ||
| <1 | 53/72 (73.6%) | 19/72 (26.4%) | ||
| ≥1 | 20/30 (66.7%) | 10/30 (33.3%) | ||
| Treatment | 106/121 | .068 | ||
| CHOP/CHOP-like | 61/76 (80.3%) | 15/76 (19.7%) | ||
| Others | 19/30 (63.3%) | 11/30 (36.7%) | ||
| Response | 96/121 | .446 | ||
| CR | 44/61 (72.1%) | 17/61 (27.9%) | ||
| PR | 13/15 (86.7%) | 2/15 (13.3%) | ||
| No response | 16/20 (80%) | 4/20 (20%) | ||
| Recurrence | 94/121 | .660 | ||
| No | 50/66 (75.8%) | 16/66 (24.2%) | ||
| Yes | 20/28 (71.4%) | 8/28 (28.6%) | ||
| State of the patient | 112/121 | .615 | ||
| Dead | 50/69 (72.5%) | 19/69 (27.5%) | ||
| Alive | 33/43 (76.7%) | 10/43 (23.3%) |
| RHOA . | Total cases . | WT . | MUT . | P . |
|---|---|---|---|---|
| DX | 121/121 | .016 | ||
| AITL | 48/73 (65.8%) | 25/73 (34.2%) | ||
| PTCL-NOS | 41/48 (85.4%) | 7/48 (14.6%) | ||
| p-ERK | 121/121 | .002 | ||
| Negative | 70/86 (81.4%) | 16/86 (18.6%) | ||
| Positive | 19/35 (54.3%) | 16/35 (45.7%) | ||
| p50 | 118/121 | .166 | ||
| Negative | 25/30 (83.8%) | 5/30 (16.7%) | ||
| Positive | 62/88 (70.5%) | 26/88 (29.5%) | ||
| p52 | 117/121 | .042 | ||
| Negative | 34/40 (85%) | 6/40 (15%) | ||
| Positive | 52/77 (67.5%) | 25/77 (32.5%) | ||
| NF-κB | 119/121 | .068 | ||
| None | 16/18 (88.9%) | 2/18 (11.1%) | ||
| p50 or p52 | 30/37 (81.1%) | 7/37 (18.9%) | ||
| Both | 42/64 (65.6%) | 22/64 (34.4%) | ||
| PD-1 | 88/121 | .024 | ||
| Negative | 24/27 (88.9%) | 3/27 (11.1%) | ||
| Positive | 40/61 (65.6%) | 21/61 (34.4%) | ||
| Sex | 117/121 | .064 | ||
| Male | 47/69 (68.1%) | 22/69 (31.9%) | ||
| Female | 40/48 (83.3%) | 4/48 (16.7%) | ||
| Age at diagnosis | 114/121 | .453 | ||
| <60 y | 33/42 (78.6%) | 9/42 (21.4%) | ||
| ≥60 y | 52/72 (72.2%) | 20/72 (27.8%) | ||
| IPI | 106/121 | .560 | ||
| Low risk | 26/32 (81.2%) | 6/32 (18.8%) | ||
| Low-intermediate risk | 18/27 (66.7%) | 9/27 (33.3%) | ||
| High-intermediate risk | 19/26 (73.1%) | 7/26 (26.9%) | ||
| High risk | 14/21 (66.7%) | 7/21 (33.3%) | ||
| PIT | 94/121 | .962 | ||
| Low risk | 10/14 (71.4%) | 4/14 (28.6%) | ||
| Low-intermediate risk | 26/35 (74.3%) | 9/35 (25.7%) | ||
| High-intermediate risk | 15/22 (68.2%) | 7/22 (31.8%) | ||
| High risk | 16/23 (69.6%) | 7/23 (30.4%) | ||
| ECOG | 102/121 | .479 | ||
| <1 | 53/72 (73.6%) | 19/72 (26.4%) | ||
| ≥1 | 20/30 (66.7%) | 10/30 (33.3%) | ||
| Treatment | 106/121 | .068 | ||
| CHOP/CHOP-like | 61/76 (80.3%) | 15/76 (19.7%) | ||
| Others | 19/30 (63.3%) | 11/30 (36.7%) | ||
| Response | 96/121 | .446 | ||
| CR | 44/61 (72.1%) | 17/61 (27.9%) | ||
| PR | 13/15 (86.7%) | 2/15 (13.3%) | ||
| No response | 16/20 (80%) | 4/20 (20%) | ||
| Recurrence | 94/121 | .660 | ||
| No | 50/66 (75.8%) | 16/66 (24.2%) | ||
| Yes | 20/28 (71.4%) | 8/28 (28.6%) | ||
| State of the patient | 112/121 | .615 | ||
| Dead | 50/69 (72.5%) | 19/69 (27.5%) | ||
| Alive | 33/43 (76.7%) | 10/43 (23.3%) |
CHOP, cyclophosphamide, vincristine, doxorubicin, prednisone; CR, total response; DX, diagnosis; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; MUT, mutated; PIT, Prognostic Index for PTCL-u; PR, partial response; WT, wild type.